Lithuanian fund EIKA Asset Management has decided to invest in Poland, choosing Warsaw and the acquisition of the Celebro office building for its first transaction. A multidisciplinary team of TPA Poland tax advisors and Baker Tilly TPA financial advisors provided advisory services to the buyer.
“Our support included comprehensive advisory to EIKA Asset Management at all stages of the transaction. Based on our analysis of the specific financial and tax aspects of the acquisition phase, current taxation, or subsequent exit scenario, the client decided on the structure under which it acquired the project. We also conducted tax and financial due diligence, and then helped EIKA secure the identified risk areas in the transaction advisory phase,” explained Patrycja Jefimiuk, Tax Advisor, Senior Manager, TPA Poland.
“We would like to congratulate the entire EIKA Asset Management team on the successful transaction. We also express our thanks for your trust and for choosing our team as your advisor on your first transaction in Poland. We believe this is the beginning of fruitful investments by EIKA in Poland. We look forward to further projects together,” added Anita Bis, Partner in Baker Tilly TPA’s Transaction Advisory Department.
Thanks go to key members of the Baker Tilly TPA and TPA Poland teams: Oskar Miller, Olga Leszczy艅ska, Alicja Ogniewska.
Eika Asset Management manages four funds that invest in commercial real estate. The fund invests in traditional commercial assets such as office buildings, shopping centers and logistics facilities, as well as light industrial facilities in the CEE region.
The Celebro office building acquired by Eika Asset Management is a modern Class A office building with approximately 7,200 sqm of space. It is located in Warsaw at ul. G艂adka 22. Built in 2019, it has a BREEAM New Construction Very Good certificate. Celebro is 100% leased, with the largest tenant in the office building being Avon, which has been present in the asset for more than 20 years. Part of the building has been adapted for a clinical research center for Pratia of the Neuca Group, one of the largest pharmaceutical companies in Central and Eastern Europe.